Bio-Path Holdings (BPTH)
(Real Time Quote from BATS)
$2.26 USD
-0.05 (-2.17%)
Updated Jun 11, 2024 01:12 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Bio-Path Holdings, Inc. [BPTH]
Reports for Purchase
Showing records 41 - 60 ( 119 total )
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
BP1002 IND Cleared for Start of a Phase 1/1b Trial in Rel/Ref AML
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2Q21: Prex AML Clinical Path Likely Defined, Prex and BP1002 Data in 2022
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Narrower-Than-Projected Net Loss; 1Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
1Q21: Potential Prex AML Clinical Path Defined, Prex & BP1002 Data by YE21
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Publishes Paper on Antisense Challenges and Advantages of Its Technology
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
BP1002 Pre-Clinical Data Presented at AACR; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Presents Encouraging Preclinical Data for BP1002 in Resistant AML at AACR
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Phase 2 Triple Combo Trial Reports Positive Preliminary Data; Reiterate Buy; Raising PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Initial Prexigebersen/Decitabine/ Venetoclax Results Highly Positive
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J